nodes	percent_of_prediction	percent_of_DWPC	metapath
Haloperidol—DRD2—nicotine dependence	0.662	1	CbGaD
Haloperidol—Abnormal behaviour—Varenicline—nicotine dependence	0.00801	0.0572	CcSEcCtD
Haloperidol—Extrapyramidal symptoms—Varenicline—nicotine dependence	0.00575	0.0411	CcSEcCtD
Haloperidol—Sexual dysfunction—Varenicline—nicotine dependence	0.00532	0.038	CcSEcCtD
Haloperidol—Libido increased—Varenicline—nicotine dependence	0.00491	0.035	CcSEcCtD
Haloperidol—Menstrual disorder—Varenicline—nicotine dependence	0.00438	0.0313	CcSEcCtD
Haloperidol—Nystagmus—Varenicline—nicotine dependence	0.00418	0.0298	CcSEcCtD
Haloperidol—Menorrhagia—Varenicline—nicotine dependence	0.00403	0.0288	CcSEcCtD
Haloperidol—Extrapyramidal disorder—Varenicline—nicotine dependence	0.00396	0.0283	CcSEcCtD
Haloperidol—Endocrine disorder—Varenicline—nicotine dependence	0.0036	0.0257	CcSEcCtD
Haloperidol—Anileridine—OPRM1—nicotine dependence	0.00354	0.419	CrCbGaD
Haloperidol—Leukocytosis—Varenicline—nicotine dependence	0.00318	0.0227	CcSEcCtD
Haloperidol—Salivary hypersecretion—Varenicline—nicotine dependence	0.0029	0.0207	CcSEcCtD
Haloperidol—Hypertonia—Varenicline—nicotine dependence	0.00262	0.0187	CcSEcCtD
Haloperidol—CBR1—cardiovascular system—nicotine dependence	0.00262	0.0645	CbGeAlD
Haloperidol—Euphoric mood—Varenicline—nicotine dependence	0.00256	0.0183	CcSEcCtD
Haloperidol—Libido decreased—Varenicline—nicotine dependence	0.00234	0.0167	CcSEcCtD
Haloperidol—Visual disturbance—Varenicline—nicotine dependence	0.00229	0.0163	CcSEcCtD
Haloperidol—Hypoglycaemia—Varenicline—nicotine dependence	0.00222	0.0159	CcSEcCtD
Haloperidol—Lethargy—Varenicline—nicotine dependence	0.00221	0.0158	CcSEcCtD
Haloperidol—Disturbance in sexual arousal—Varenicline—nicotine dependence	0.00215	0.0154	CcSEcCtD
Haloperidol—H1F0—cardiovascular system—nicotine dependence	0.00214	0.0529	CbGeAlD
Haloperidol—Psychotic disorder—Varenicline—nicotine dependence	0.00212	0.0151	CcSEcCtD
Haloperidol—DRD4—brain—nicotine dependence	0.00206	0.0509	CbGeAlD
Haloperidol—Urinary retention—Varenicline—nicotine dependence	0.00206	0.0147	CcSEcCtD
Haloperidol—CBR1—midbrain—nicotine dependence	0.00204	0.0504	CbGeAlD
Haloperidol—Liver function test abnormal—Varenicline—nicotine dependence	0.002	0.0143	CcSEcCtD
Haloperidol—Breast disorder—Varenicline—nicotine dependence	0.00196	0.014	CcSEcCtD
Haloperidol—Dysphagia—Varenicline—nicotine dependence	0.00187	0.0134	CcSEcCtD
Haloperidol—Droperidol—DRD2—nicotine dependence	0.00177	0.21	CrCbGaD
Haloperidol—GRIN2B—brain—nicotine dependence	0.00173	0.0427	CbGeAlD
Haloperidol—Erectile dysfunction—Varenicline—nicotine dependence	0.00172	0.0123	CcSEcCtD
Haloperidol—HTR1B—cardiovascular system—nicotine dependence	0.00171	0.0423	CbGeAlD
Haloperidol—Photosensitivity reaction—Varenicline—nicotine dependence	0.00171	0.0122	CcSEcCtD
Haloperidol—Weight increased—Varenicline—nicotine dependence	0.0017	0.0122	CcSEcCtD
Haloperidol—Hyperglycaemia—Varenicline—nicotine dependence	0.00169	0.0121	CcSEcCtD
Haloperidol—H1F0—midbrain—nicotine dependence	0.00167	0.0413	CbGeAlD
Haloperidol—Depression—Varenicline—nicotine dependence	0.00166	0.0119	CcSEcCtD
Haloperidol—HTR1D—cardiovascular system—nicotine dependence	0.00166	0.041	CbGeAlD
Haloperidol—DRD1—midbrain—nicotine dependence	0.00165	0.0408	CbGeAlD
Haloperidol—Hepatobiliary disease—Varenicline—nicotine dependence	0.00158	0.0113	CcSEcCtD
Haloperidol—HTR2B—cardiovascular system—nicotine dependence	0.00154	0.0381	CbGeAlD
Haloperidol—Hallucination—Varenicline—nicotine dependence	0.00149	0.0107	CcSEcCtD
Haloperidol—Urinary tract disorder—Varenicline—nicotine dependence	0.00148	0.0106	CcSEcCtD
Haloperidol—Connective tissue disorder—Varenicline—nicotine dependence	0.00147	0.0105	CcSEcCtD
Haloperidol—Urethral disorder—Varenicline—nicotine dependence	0.00147	0.0105	CcSEcCtD
Haloperidol—DRD3—brain—nicotine dependence	0.00145	0.0358	CbGeAlD
Haloperidol—Visual impairment—Varenicline—nicotine dependence	0.00144	0.0103	CcSEcCtD
Haloperidol—Eye disorder—Varenicline—nicotine dependence	0.0014	0.01	CcSEcCtD
Haloperidol—Cardiac disorder—Varenicline—nicotine dependence	0.00139	0.00994	CcSEcCtD
Haloperidol—Angiopathy—Varenicline—nicotine dependence	0.00136	0.00971	CcSEcCtD
Haloperidol—Immune system disorder—Varenicline—nicotine dependence	0.00135	0.00967	CcSEcCtD
Haloperidol—Mediastinal disorder—Varenicline—nicotine dependence	0.00135	0.00965	CcSEcCtD
Haloperidol—HTR1B—midbrain—nicotine dependence	0.00134	0.033	CbGeAlD
Haloperidol—Mental disorder—Varenicline—nicotine dependence	0.00131	0.00938	CcSEcCtD
Haloperidol—Malnutrition—Varenicline—nicotine dependence	0.0013	0.00932	CcSEcCtD
Haloperidol—HTR1D—midbrain—nicotine dependence	0.0013	0.032	CbGeAlD
Haloperidol—CBR1—brain—nicotine dependence	0.00128	0.0317	CbGeAlD
Haloperidol—Muscle spasms—Varenicline—nicotine dependence	0.00125	0.00896	CcSEcCtD
Haloperidol—KCNH2—cardiovascular system—nicotine dependence	0.00123	0.0304	CbGeAlD
Haloperidol—Vision blurred—Varenicline—nicotine dependence	0.00123	0.00878	CcSEcCtD
Haloperidol—Tremor—Varenicline—nicotine dependence	0.00122	0.00873	CcSEcCtD
Haloperidol—SIGMAR1—midbrain—nicotine dependence	0.00121	0.0298	CbGeAlD
Haloperidol—Anaemia—Varenicline—nicotine dependence	0.00121	0.00861	CcSEcCtD
Haloperidol—Agitation—Varenicline—nicotine dependence	0.0012	0.00856	CcSEcCtD
Haloperidol—Vertigo—Varenicline—nicotine dependence	0.00117	0.00837	CcSEcCtD
Haloperidol—Sertindole—DRD2—nicotine dependence	0.00114	0.135	CrCbGaD
Haloperidol—Convulsion—Varenicline—nicotine dependence	0.00113	0.00808	CcSEcCtD
Haloperidol—Hypertension—Varenicline—nicotine dependence	0.00113	0.00805	CcSEcCtD
Haloperidol—Anxiety—Varenicline—nicotine dependence	0.00111	0.00791	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.0011	0.00788	CcSEcCtD
Haloperidol—Dry mouth—Varenicline—nicotine dependence	0.00109	0.00776	CcSEcCtD
Haloperidol—Oedema—Varenicline—nicotine dependence	0.00106	0.00761	CcSEcCtD
Haloperidol—Loperamide—OPRM1—nicotine dependence	0.00106	0.126	CrCbGaD
Haloperidol—H1F0—brain—nicotine dependence	0.00105	0.0259	CbGeAlD
Haloperidol—Nervous system disorder—Varenicline—nicotine dependence	0.00104	0.00746	CcSEcCtD
Haloperidol—Thrombocytopenia—Varenicline—nicotine dependence	0.00104	0.00745	CcSEcCtD
Haloperidol—Tachycardia—Varenicline—nicotine dependence	0.00104	0.00742	CcSEcCtD
Haloperidol—DRD1—brain—nicotine dependence	0.00104	0.0256	CbGeAlD
Haloperidol—Skin disorder—Varenicline—nicotine dependence	0.00103	0.00739	CcSEcCtD
Haloperidol—Hyperhidrosis—Varenicline—nicotine dependence	0.00103	0.00735	CcSEcCtD
Haloperidol—Anorexia—Varenicline—nicotine dependence	0.00102	0.00725	CcSEcCtD
Haloperidol—CYP2C9—cardiovascular system—nicotine dependence	0.001	0.0247	CbGeAlD
Haloperidol—Hypotension—Varenicline—nicotine dependence	0.000995	0.00711	CcSEcCtD
Haloperidol—DRD2—midbrain—nicotine dependence	0.000976	0.0241	CbGeAlD
Haloperidol—Insomnia—Varenicline—nicotine dependence	0.000963	0.00688	CcSEcCtD
Haloperidol—KCNH2—midbrain—nicotine dependence	0.000962	0.0237	CbGeAlD
Haloperidol—Dyspnoea—Varenicline—nicotine dependence	0.000949	0.00678	CcSEcCtD
Haloperidol—Somnolence—Varenicline—nicotine dependence	0.000947	0.00676	CcSEcCtD
Haloperidol—Dyspepsia—Varenicline—nicotine dependence	0.000937	0.0067	CcSEcCtD
Haloperidol—Fluspirilene—DRD2—nicotine dependence	0.000931	0.11	CrCbGaD
Haloperidol—Decreased appetite—Varenicline—nicotine dependence	0.000926	0.00661	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Varenicline—nicotine dependence	0.000919	0.00657	CcSEcCtD
Haloperidol—Constipation—Varenicline—nicotine dependence	0.000911	0.0065	CcSEcCtD
Haloperidol—Feeling abnormal—Varenicline—nicotine dependence	0.000878	0.00627	CcSEcCtD
Haloperidol—Urticaria—Varenicline—nicotine dependence	0.000846	0.00604	CcSEcCtD
Haloperidol—Body temperature increased—Varenicline—nicotine dependence	0.000842	0.00601	CcSEcCtD
Haloperidol—HTR1B—brain—nicotine dependence	0.000841	0.0208	CbGeAlD
Haloperidol—HTR2A—cardiovascular system—nicotine dependence	0.000825	0.0203	CbGeAlD
Haloperidol—HTR1D—brain—nicotine dependence	0.000815	0.0201	CbGeAlD
Haloperidol—Hypersensitivity—Varenicline—nicotine dependence	0.000785	0.0056	CcSEcCtD
Haloperidol—SIGMAR1—brain—nicotine dependence	0.000759	0.0187	CbGeAlD
Haloperidol—HTR2B—brain—nicotine dependence	0.000758	0.0187	CbGeAlD
Haloperidol—Pruritus—Varenicline—nicotine dependence	0.000753	0.00538	CcSEcCtD
Haloperidol—Diarrhoea—Varenicline—nicotine dependence	0.000729	0.0052	CcSEcCtD
Haloperidol—Dizziness—Varenicline—nicotine dependence	0.000704	0.00503	CcSEcCtD
Haloperidol—Vomiting—Varenicline—nicotine dependence	0.000677	0.00484	CcSEcCtD
Haloperidol—Rash—Varenicline—nicotine dependence	0.000671	0.0048	CcSEcCtD
Haloperidol—Dermatitis—Varenicline—nicotine dependence	0.000671	0.00479	CcSEcCtD
Haloperidol—Headache—Varenicline—nicotine dependence	0.000667	0.00477	CcSEcCtD
Haloperidol—HTR2A—midbrain—nicotine dependence	0.000644	0.0159	CbGeAlD
Haloperidol—Nausea—Varenicline—nicotine dependence	0.000633	0.00452	CcSEcCtD
Haloperidol—DRD2—brain—nicotine dependence	0.000613	0.0151	CbGeAlD
Haloperidol—KCNH2—brain—nicotine dependence	0.000604	0.0149	CbGeAlD
Haloperidol—ABCB1—cardiovascular system—nicotine dependence	0.00054	0.0133	CbGeAlD
Haloperidol—CYP1A1—brain—nicotine dependence	0.00051	0.0126	CbGeAlD
Haloperidol—HRH1—brain—nicotine dependence	0.000484	0.012	CbGeAlD
Haloperidol—ABCB1—midbrain—nicotine dependence	0.000422	0.0104	CbGeAlD
Haloperidol—HTR2A—brain—nicotine dependence	0.000405	0.00998	CbGeAlD
Haloperidol—CYP2D6—brain—nicotine dependence	0.000369	0.0091	CbGeAlD
Haloperidol—HTR2A—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.000361	0.00242	CbGpPWpGaD
Haloperidol—DRD1—GPCR ligand binding—TAS2R16—nicotine dependence	0.000343	0.0023	CbGpPWpGaD
Haloperidol—DRD3—GPCR ligand binding—TAS2R16—nicotine dependence	0.000339	0.00227	CbGpPWpGaD
Haloperidol—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00033	0.00221	CbGpPWpGaD
Haloperidol—GRIN2B—Neuronal System—CHRNB2—nicotine dependence	0.000327	0.00219	CbGpPWpGaD
Haloperidol—KCNH2—Neuronal System—CHRNA3—nicotine dependence	0.000317	0.00213	CbGpPWpGaD
Haloperidol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.000314	0.0021	CbGpPWpGaD
Haloperidol—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00031	0.00208	CbGpPWpGaD
Haloperidol—CYP3A5—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000308	0.00207	CbGpPWpGaD
Haloperidol—GRIN2B—Neuronal System—CHRNA4—nicotine dependence	0.000297	0.00199	CbGpPWpGaD
Haloperidol—DRD4—Circadian rythm related genes—CHRNB2—nicotine dependence	0.000294	0.00197	CbGpPWpGaD
Haloperidol—CYP1A1—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000291	0.00195	CbGpPWpGaD
Haloperidol—CYP3A5—Biological oxidations—CYP2A7—nicotine dependence	0.000291	0.00195	CbGpPWpGaD
Haloperidol—CYP3A5—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000287	0.00192	CbGpPWpGaD
Haloperidol—KCNH2—Neuronal System—CHRNB2—nicotine dependence	0.000279	0.00187	CbGpPWpGaD
Haloperidol—EBP—Metabolism—CYP2A7—nicotine dependence	0.000276	0.00185	CbGpPWpGaD
Haloperidol—HTR1D—G alpha (i) signalling events—OPRM1—nicotine dependence	0.000276	0.00185	CbGpPWpGaD
Haloperidol—CYP1A1—Biological oxidations—CYP2A7—nicotine dependence	0.000275	0.00184	CbGpPWpGaD
Haloperidol—CBR1—Metabolism—CYP2A7—nicotine dependence	0.000272	0.00182	CbGpPWpGaD
Haloperidol—CYP1A1—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000271	0.00181	CbGpPWpGaD
Haloperidol—HTR1B—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00027	0.00181	CbGpPWpGaD
Haloperidol—DRD4—G alpha (i) signalling events—OPRM1—nicotine dependence	0.000266	0.00178	CbGpPWpGaD
Haloperidol—ABCB1—brain—nicotine dependence	0.000265	0.00654	CbGeAlD
Haloperidol—DRD1—Circadian rythm related genes—CHRNB2—nicotine dependence	0.000265	0.00178	CbGpPWpGaD
Haloperidol—DRD3—Circadian rythm related genes—CHRNB2—nicotine dependence	0.000261	0.00175	CbGpPWpGaD
Haloperidol—DRD2—GPCR ligand binding—TAS2R16—nicotine dependence	0.000259	0.00174	CbGpPWpGaD
Haloperidol—HTR1D—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000256	0.00171	CbGpPWpGaD
Haloperidol—HTR2A—GPCR ligand binding—TAS2R16—nicotine dependence	0.000255	0.00171	CbGpPWpGaD
Haloperidol—HRH1—GPCR ligand binding—TAS2R16—nicotine dependence	0.000255	0.00171	CbGpPWpGaD
Haloperidol—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000254	0.0017	CbGpPWpGaD
Haloperidol—KCNH2—Neuronal System—CHRNA4—nicotine dependence	0.000254	0.0017	CbGpPWpGaD
Haloperidol—HTR1B—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00025	0.00168	CbGpPWpGaD
Haloperidol—DRD4—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000246	0.00165	CbGpPWpGaD
Haloperidol—HTR2A—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.000241	0.00162	CbGpPWpGaD
Haloperidol—CYP2C19—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000238	0.0016	CbGpPWpGaD
Haloperidol—DRD3—G alpha (i) signalling events—OPRM1—nicotine dependence	0.000236	0.00158	CbGpPWpGaD
Haloperidol—HTR2B—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000235	0.00158	CbGpPWpGaD
Haloperidol—CYP2C19—Biological oxidations—CYP2A7—nicotine dependence	0.000225	0.00151	CbGpPWpGaD
Haloperidol—HTR1D—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000224	0.0015	CbGpPWpGaD
Haloperidol—DRD1—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000222	0.00149	CbGpPWpGaD
Haloperidol—CYP2C19—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000222	0.00149	CbGpPWpGaD
Haloperidol—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000219	0.00147	CbGpPWpGaD
Haloperidol—HTR1D—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000219	0.00147	CbGpPWpGaD
Haloperidol—HTR1B—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000219	0.00147	CbGpPWpGaD
Haloperidol—DRD3—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000219	0.00147	CbGpPWpGaD
Haloperidol—HTR2A—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.000219	0.00147	CbGpPWpGaD
Haloperidol—DRD4—Circadian rythm related genes—DRD2—nicotine dependence	0.000218	0.00146	CbGpPWpGaD
Haloperidol—CYP2C9—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000217	0.00146	CbGpPWpGaD
Haloperidol—DRD4—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000216	0.00145	CbGpPWpGaD
Haloperidol—HTR1B—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000215	0.00144	CbGpPWpGaD
Haloperidol—DRD4—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000211	0.00142	CbGpPWpGaD
Haloperidol—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.000207	0.00139	CbGpPWpGaD
Haloperidol—HTR2B—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000206	0.00138	CbGpPWpGaD
Haloperidol—CYP2C9—Biological oxidations—CYP2A7—nicotine dependence	0.000205	0.00137	CbGpPWpGaD
Haloperidol—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000204	0.00137	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—TAS2R16—nicotine dependence	0.000203	0.00136	CbGpPWpGaD
Haloperidol—CYP2C9—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000202	0.00135	CbGpPWpGaD
Haloperidol—HTR2B—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000202	0.00135	CbGpPWpGaD
Haloperidol—DRD2—Circadian rythm related genes—CHRNB2—nicotine dependence	0.0002	0.00134	CbGpPWpGaD
Haloperidol—HTR1D—G alpha (i) signalling events—DRD2—nicotine dependence	0.000199	0.00134	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—TAS2R16—nicotine dependence	0.000199	0.00133	CbGpPWpGaD
Haloperidol—DRD1—Circadian rythm related genes—DRD2—nicotine dependence	0.000196	0.00131	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—TAS2R16—nicotine dependence	0.000196	0.00131	CbGpPWpGaD
Haloperidol—HTR1B—G alpha (i) signalling events—DRD2—nicotine dependence	0.000195	0.00131	CbGpPWpGaD
Haloperidol—DRD1—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000194	0.0013	CbGpPWpGaD
Haloperidol—DRD3—Circadian rythm related genes—DRD2—nicotine dependence	0.000193	0.0013	CbGpPWpGaD
Haloperidol—DRD4—G alpha (i) signalling events—DRD2—nicotine dependence	0.000192	0.00129	CbGpPWpGaD
Haloperidol—DRD3—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000191	0.00128	CbGpPWpGaD
Haloperidol—DRD1—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00019	0.00127	CbGpPWpGaD
Haloperidol—DRD3—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000188	0.00126	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—TAS2R16—nicotine dependence	0.000187	0.00125	CbGpPWpGaD
Haloperidol—CYP1A2—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000186	0.00124	CbGpPWpGaD
Haloperidol—HTR1D—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000185	0.00124	CbGpPWpGaD
Haloperidol—HTR1B—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000181	0.00121	CbGpPWpGaD
Haloperidol—DRD2—G alpha (i) signalling events—OPRM1—nicotine dependence	0.000181	0.00121	CbGpPWpGaD
Haloperidol—DRD4—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000178	0.00119	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—TAS2R16—nicotine dependence	0.000176	0.00118	CbGpPWpGaD
Haloperidol—HTR1D—GPCR downstream signaling—FGD1—nicotine dependence	0.000176	0.00118	CbGpPWpGaD
Haloperidol—CYP1A2—Biological oxidations—CYP2A7—nicotine dependence	0.000175	0.00117	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—TAS2R16—nicotine dependence	0.000174	0.00117	CbGpPWpGaD
Haloperidol—CYP1A2—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000173	0.00116	CbGpPWpGaD
Haloperidol—HTR1B—GPCR downstream signaling—FGD1—nicotine dependence	0.000172	0.00115	CbGpPWpGaD
Haloperidol—DRD3—G alpha (i) signalling events—DRD2—nicotine dependence	0.000171	0.00114	CbGpPWpGaD
Haloperidol—HTR2B—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00017	0.00114	CbGpPWpGaD
Haloperidol—DRD4—GPCR downstream signaling—FGD1—nicotine dependence	0.000169	0.00113	CbGpPWpGaD
Haloperidol—DRD2—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000168	0.00112	CbGpPWpGaD
Haloperidol—HTR1D—GPCR ligand binding—OPRM1—nicotine dependence	0.000167	0.00112	CbGpPWpGaD
Haloperidol—HTR2A—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000165	0.0011	CbGpPWpGaD
Haloperidol—HRH1—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000164	0.0011	CbGpPWpGaD
Haloperidol—HTR1B—GPCR ligand binding—OPRM1—nicotine dependence	0.000163	0.0011	CbGpPWpGaD
Haloperidol—HTR2B—GPCR downstream signaling—FGD1—nicotine dependence	0.000161	0.00108	CbGpPWpGaD
Haloperidol—DRD4—GPCR ligand binding—OPRM1—nicotine dependence	0.000161	0.00108	CbGpPWpGaD
Haloperidol—DRD1—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00016	0.00108	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—FGD1—nicotine dependence	0.000159	0.00107	CbGpPWpGaD
Haloperidol—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000158	0.00106	CbGpPWpGaD
Haloperidol—DRD3—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000158	0.00106	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—FGD1—nicotine dependence	0.000156	0.00105	CbGpPWpGaD
Haloperidol—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000155	0.00104	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—FGD1—nicotine dependence	0.000154	0.00103	CbGpPWpGaD
Haloperidol—HTR2B—GPCR ligand binding—OPRM1—nicotine dependence	0.000154	0.00103	CbGpPWpGaD
Haloperidol—DRD4—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000153	0.00102	CbGpPWpGaD
Haloperidol—DRD1—GPCR downstream signaling—FGD1—nicotine dependence	0.000152	0.00102	CbGpPWpGaD
Haloperidol—DRD3—GPCR downstream signaling—FGD1—nicotine dependence	0.00015	0.00101	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—FGD1—nicotine dependence	0.000147	0.000983	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000147	0.000982	CbGpPWpGaD
Haloperidol—HTR2B—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000146	0.000977	CbGpPWpGaD
Haloperidol—DRD1—GPCR ligand binding—OPRM1—nicotine dependence	0.000145	0.00097	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000144	0.000966	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000144	0.000964	CbGpPWpGaD
Haloperidol—DRD2—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000144	0.000962	CbGpPWpGaD
Haloperidol—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000143	0.000961	CbGpPWpGaD
Haloperidol—DRD3—GPCR ligand binding—OPRM1—nicotine dependence	0.000143	0.000958	CbGpPWpGaD
Haloperidol—HTR2A—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000141	0.000947	CbGpPWpGaD
Haloperidol—HRH1—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000141	0.000945	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—FGD1—nicotine dependence	0.000138	0.000927	CbGpPWpGaD
Haloperidol—DRD1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000137	0.000921	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—FGD1—nicotine dependence	0.000136	0.000915	CbGpPWpGaD
Haloperidol—DRD3—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000136	0.000909	CbGpPWpGaD
Haloperidol—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000135	0.000906	CbGpPWpGaD
Haloperidol—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000133	0.000893	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—TAS2R16—nicotine dependence	0.000133	0.000892	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—TAS2R16—nicotine dependence	0.000131	0.000878	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—TAS2R16—nicotine dependence	0.000131	0.000876	CbGpPWpGaD
Haloperidol—HTR1D—GPCR ligand binding—DRD2—nicotine dependence	0.000121	0.000809	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—TAS2R16—nicotine dependence	0.00012	0.000805	CbGpPWpGaD
Haloperidol—HTR2A—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000119	0.000799	CbGpPWpGaD
Haloperidol—HRH1—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000119	0.000797	CbGpPWpGaD
Haloperidol—HTR1B—GPCR ligand binding—DRD2—nicotine dependence	0.000118	0.000792	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—TAS2R16—nicotine dependence	0.000118	0.000788	CbGpPWpGaD
Haloperidol—DRD4—GPCR ligand binding—DRD2—nicotine dependence	0.000116	0.000779	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TAS2R16—nicotine dependence	0.000116	0.000775	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—FGD1—nicotine dependence	0.000115	0.000771	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—FGD1—nicotine dependence	0.000113	0.000758	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—FGD1—nicotine dependence	0.000113	0.000757	CbGpPWpGaD
Haloperidol—HTR2B—GPCR ligand binding—DRD2—nicotine dependence	0.000111	0.000744	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TAS2R16—nicotine dependence	0.00011	0.00074	CbGpPWpGaD
Haloperidol—DRD2—GPCR ligand binding—OPRM1—nicotine dependence	0.000109	0.000733	CbGpPWpGaD
Haloperidol—HTR2A—GPCR ligand binding—OPRM1—nicotine dependence	0.000108	0.000721	CbGpPWpGaD
Haloperidol—HRH1—GPCR ligand binding—OPRM1—nicotine dependence	0.000107	0.000719	CbGpPWpGaD
Haloperidol—DRD1—GPCR ligand binding—DRD2—nicotine dependence	0.000105	0.000702	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—FGD1—nicotine dependence	0.000104	0.0007	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TAS2R16—nicotine dependence	0.000104	0.000698	CbGpPWpGaD
Haloperidol—DRD3—GPCR ligand binding—DRD2—nicotine dependence	0.000103	0.000692	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—FGD1—nicotine dependence	0.000103	0.000689	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TAS2R16—nicotine dependence	0.000103	0.000689	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—FGD1—nicotine dependence	0.000103	0.000687	CbGpPWpGaD
Haloperidol—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000102	0.000684	CbGpPWpGaD
Haloperidol—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000102	0.000683	CbGpPWpGaD
Haloperidol—HTR1D—GPCR downstream signaling—OPRM1—nicotine dependence	9.43e-05	0.000632	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—FGD1—nicotine dependence	9.42e-05	0.000631	CbGpPWpGaD
Haloperidol—HTR1B—GPCR downstream signaling—OPRM1—nicotine dependence	9.24e-05	0.000619	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—FGD1—nicotine dependence	9.22e-05	0.000618	CbGpPWpGaD
Haloperidol—DRD4—GPCR downstream signaling—OPRM1—nicotine dependence	9.09e-05	0.000609	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—FGD1—nicotine dependence	9.07e-05	0.000608	CbGpPWpGaD
Haloperidol—HTR2B—GPCR downstream signaling—OPRM1—nicotine dependence	8.68e-05	0.000582	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—FGD1—nicotine dependence	8.66e-05	0.000581	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—OPRM1—nicotine dependence	8.57e-05	0.000574	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—OPRM1—nicotine dependence	8.39e-05	0.000562	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—AKR1B10—nicotine dependence	8.32e-05	0.000558	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—OPRM1—nicotine dependence	8.25e-05	0.000553	CbGpPWpGaD
Haloperidol—DRD1—GPCR downstream signaling—OPRM1—nicotine dependence	8.18e-05	0.000548	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—CYP2A7—nicotine dependence	8.17e-05	0.000548	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—FGD1—nicotine dependence	8.17e-05	0.000548	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—AKR1B10—nicotine dependence	8.15e-05	0.000546	CbGpPWpGaD
Haloperidol—DRD3—GPCR downstream signaling—OPRM1—nicotine dependence	8.07e-05	0.000541	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—FGD1—nicotine dependence	8.06e-05	0.00054	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—AKR1B10—nicotine dependence	8.02e-05	0.000537	CbGpPWpGaD
Haloperidol—ABCB1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	8.01e-05	0.000537	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—OPRM1—nicotine dependence	7.88e-05	0.000528	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TAS2R16—nicotine dependence	7.86e-05	0.000527	CbGpPWpGaD
Haloperidol—HTR2A—GPCR ligand binding—DRD2—nicotine dependence	7.78e-05	0.000521	CbGpPWpGaD
Haloperidol—HRH1—GPCR ligand binding—DRD2—nicotine dependence	7.76e-05	0.00052	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TAS2R16—nicotine dependence	7.73e-05	0.000518	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TAS2R16—nicotine dependence	7.72e-05	0.000517	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—AKR1B10—nicotine dependence	7.65e-05	0.000513	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—OPRM1—nicotine dependence	7.43e-05	0.000498	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—OPRM1—nicotine dependence	7.33e-05	0.000491	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—AKR1B10—nicotine dependence	7.22e-05	0.000484	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—AKR1B10—nicotine dependence	7.12e-05	0.000477	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—CYP2A7—nicotine dependence	6.87e-05	0.000461	CbGpPWpGaD
Haloperidol—HTR1D—GPCR downstream signaling—DRD2—nicotine dependence	6.82e-05	0.000457	CbGpPWpGaD
Haloperidol—HTR1B—GPCR downstream signaling—DRD2—nicotine dependence	6.68e-05	0.000448	CbGpPWpGaD
Haloperidol—DRD4—GPCR downstream signaling—DRD2—nicotine dependence	6.57e-05	0.00044	CbGpPWpGaD
Haloperidol—HTR2B—GPCR downstream signaling—DRD2—nicotine dependence	6.27e-05	0.00042	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—DRD2—nicotine dependence	6.19e-05	0.000415	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—OPRM1—nicotine dependence	6.18e-05	0.000414	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—FGD1—nicotine dependence	6.17e-05	0.000413	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—OPRM1—nicotine dependence	6.08e-05	0.000407	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—FGD1—nicotine dependence	6.07e-05	0.000407	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—OPRM1—nicotine dependence	6.06e-05	0.000407	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—DRD2—nicotine dependence	6.06e-05	0.000406	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—FGD1—nicotine dependence	6.06e-05	0.000406	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—DRD2—nicotine dependence	5.97e-05	0.0004	CbGpPWpGaD
Haloperidol—DRD1—GPCR downstream signaling—DRD2—nicotine dependence	5.92e-05	0.000396	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—WASF2—nicotine dependence	5.86e-05	0.000393	CbGpPWpGaD
Haloperidol—DRD3—GPCR downstream signaling—DRD2—nicotine dependence	5.84e-05	0.000391	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—WASF2—nicotine dependence	5.74e-05	0.000385	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—DRD2—nicotine dependence	5.7e-05	0.000382	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—WASF2—nicotine dependence	5.65e-05	0.000379	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—WASF1—nicotine dependence	5.62e-05	0.000377	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—OPRM1—nicotine dependence	5.61e-05	0.000376	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—OPRM1—nicotine dependence	5.52e-05	0.00037	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—OPRM1—nicotine dependence	5.51e-05	0.000369	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—WASF1—nicotine dependence	5.5e-05	0.000369	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—AKR1B10—nicotine dependence	5.45e-05	0.000365	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—WASF1—nicotine dependence	5.41e-05	0.000363	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—WASF2—nicotine dependence	5.39e-05	0.000361	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—DRD2—nicotine dependence	5.37e-05	0.00036	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—AKR1B10—nicotine dependence	5.36e-05	0.000359	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—AKR1B10—nicotine dependence	5.35e-05	0.000359	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—DRD2—nicotine dependence	5.3e-05	0.000355	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—WASF1—nicotine dependence	5.17e-05	0.000346	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—WASF2—nicotine dependence	5.08e-05	0.000341	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—OPRM1—nicotine dependence	5.06e-05	0.000339	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—WASF2—nicotine dependence	5.02e-05	0.000336	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—CYP2A7—nicotine dependence	4.97e-05	0.000333	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—OPRM1—nicotine dependence	4.95e-05	0.000332	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—OPRM1—nicotine dependence	4.88e-05	0.000327	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—WASF1—nicotine dependence	4.87e-05	0.000327	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—WASF1—nicotine dependence	4.81e-05	0.000322	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—CYP2A7—nicotine dependence	4.69e-05	0.000315	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—OPRM1—nicotine dependence	4.65e-05	0.000312	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—DRD2—nicotine dependence	4.39e-05	0.000295	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—OPRM1—nicotine dependence	4.39e-05	0.000294	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—DRD2—nicotine dependence	4.38e-05	0.000294	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—OPRM1—nicotine dependence	4.33e-05	0.00029	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—DRD2—nicotine dependence	3.99e-05	0.000267	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—DRD2—nicotine dependence	3.98e-05	0.000267	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—CYP2A7—nicotine dependence	3.84e-05	0.000258	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—WASF2—nicotine dependence	3.84e-05	0.000257	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—WASF2—nicotine dependence	3.78e-05	0.000253	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—WASF2—nicotine dependence	3.77e-05	0.000253	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—CYP2A7—nicotine dependence	3.75e-05	0.000251	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—WASF1—nicotine dependence	3.68e-05	0.000247	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—DRD2—nicotine dependence	3.66e-05	0.000245	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—WASF1—nicotine dependence	3.62e-05	0.000243	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—WASF1—nicotine dependence	3.61e-05	0.000242	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—DRD2—nicotine dependence	3.58e-05	0.00024	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CYP2A7—nicotine dependence	3.53e-05	0.000237	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—DRD2—nicotine dependence	3.52e-05	0.000236	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CYP2A7—nicotine dependence	3.5e-05	0.000235	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—DRD2—nicotine dependence	3.36e-05	0.000226	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—OPRM1—nicotine dependence	3.31e-05	0.000222	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—OPRM1—nicotine dependence	3.26e-05	0.000219	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—OPRM1—nicotine dependence	3.25e-05	0.000218	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—DRD2—nicotine dependence	3.17e-05	0.000213	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—DRD2—nicotine dependence	3.13e-05	0.00021	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CYP2A7—nicotine dependence	2.99e-05	0.000201	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—DRD2—nicotine dependence	2.36e-05	0.000158	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—DRD2—nicotine dependence	2.35e-05	0.000158	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CYP2A7—nicotine dependence	2.31e-05	0.000155	CbGpPWpGaD
